Axa’s Meridian Bioscience Inc VIVO Stock Holding History

Axa’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,100	Closed	-$148K	–	1270
2019 Q4	$148K	Hold	15,100	–	–	﹤0.01%	1145
2019 Q3	$143K	Buy	+15,100	New	+$159K	﹤0.01%	1265

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Axa's VIVO Position: Q1 2020 in Review

Axa sold out of Meridian Bioscience Inc (VIVO) in Q1 2020, closing a stake of 15,100 shares — an estimated $148K sold.

Axa first reported a position in VIVO in Q3 2019 and held it in 2 quarters. The position peaked at $148K in Q4 2019. 168 funds tracked by Wall St. Rank hold VIVO as of Q1 2020.

Axa reported no remaining Meridian Bioscience Inc position as of Q1 2020 after selling out during the quarter.
Axa sold 15,100 Meridian Bioscience Inc shares in Q1 2020, an estimated $148K.
Axa first reported a position in Meridian Bioscience Inc in Q3 2019 and held it in 2 quarters.
Axa's Meridian Bioscience Inc position peaked at $148K in Q4 2019.
168 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2020.

Based on Axa's 13F filing for Q1 2020, filed 15 May 2020.